EUCTR2012-001575-37-ES进行中（未招募）1 期
A Study of HSP90 Inhibitor AT13387 Alone and in Combination withCrizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC).
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects who meet all of the following criteria will be eligible to participate in the study:
- •1. Men or women ? 18 years of age;
- •2. Have a histologically or cytologically confirmed NSCLC that is ALK+ or has other mutations or rearrangements that are potentially sensitive to crizotinib and have been receiving or have received crizotinib, regardless of other prior anticancer therapies including other ALK inhibitors;
- •3. Presence of disease as described in Inclusion Criterion 4 for the different parts of the study;
- •4.a. In Part A, subjects must have received and been tolerant to at least 8 weeks of crizotinib 250 mg BID in the past regardless of when it was taken and the number of other intervening anticancer therapies, including other ALK inhibitors that may have been taken since the last dose of crizotinib. In part A, subjects with any response category may be enrolled as long as there is a chance of potential added benefit from continuing crizotinib in combination with AT13387 even if there is evidence of disease progression while on crizotinib monotherapy;
- •b. In Part B, subjects who are currently receiving and tolerating crizotinib and have not progressed by RECIST 1.1. or have not yet started but are eligible to receive crizotinib; and
- •c. In Part C, only subjects who are progressing or had previously progressed based on RECIST 1.1 at any time on crizotinib (including those who went on to receive other therapy including other ALK inhibitors before enrollment) will be enrolled;
- •5. Eastern Cooperative Oncology Group Performance Status ?1 for Part A and ?2 for Parts B and C;
- •6. Have adequate bone marrow function defined as absolute neutrophil count >1.5 K/?L and platelet count >75 K/?L;
- •7. Have adequate hepatic function, defined as bilirubin ?1.5 × upper limit of normal (ULN) and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?2.5 × ULN (ALT and AST ?5 × ULN, if liver metastases are present);
- •8. Have adequate renal function, defined as serum creatinine ?1.25 × ULN or estimated creatinine clearance >50 mL/min;
- •9. Have adequate cardiac function and normal cardiac repolarization defined as:
- •a. QTc ?480 msec and
- •b. Left ventricular ejection fraction ? 50% or within institutional limits of normal by echocardiogram or multigated acquisition scan;
- •10. Female subjects who are either:
- •a. Not pregnant (must have a negative pregnancy test at screening) or breastfeeding and not planning to become pregnant during the study;
- •b. Not of childbearing potential, defined as one who has been postmenopausal (no menses AND either age ?65 years or folliclestimulating hormone levels in the menopausal range) for at least 1 year, has been surgically sterilized by bilateral oophorectomy, or has had a hysterectomy;
- •11. Subjects and their female partners with reproductive potential must agree to use effective contraceptive measures during the study and for 3 months following the last dose of the study drug. Effective contraception includes methods such as oral contraceptives, double-barrier method
- •(condom plus spermicide or diaphragm), or abstaining from sexual intercourse; and
- •12. Able and willing to provide written informed consent and to comply with the protocol and study procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 228
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 160
排除标准
- •Subjects who meet any of the following criteria will be excluded from the study:
- •1. Prior anti-cancer treatment with any heat shock protein 90 (HSP90) inhibitor;
- •2. Have received chemotherapy, radiation therapy, or other anticancer treatment other than crizotinib within 3 weeks prior to the first dose of study drug unless the washout period of those treatments has clearly exceeded 5 pharmacokinetic half-lives and any associated clinically significant toxicity has resolved to ?Grade 1;
- •3. Subjects with a prior malignancy other than adequately treated basal or squamous cell carcinoma of the skin, superficial bladder cancer, lowgrade cervical cancer, non-metastatic prostate cancer with normal PSA, or other cancer from which the subject has been disease-free for at least 3 years;
- •4. Known symptomatic brain or central nervous system metastases (Note: Patients with asymptomatic brain metastases or any brain metastases that have been stable for ? 4 weeks may be included);
- •5. Documented QTc prolongation >480 msec related to crizotinib on multiple measurements in electrocardiograms (ECGs) during prior
- •treatment with crizotinib;
- •6. ? Grade 2 bilirubin or transaminases on multiple measurements related to crizotinib while receiving crizotinib;
- •7. ? Grade 2 visual disturbances related to crizotinib while receiving crizotinib treatment;
- •8. Congenital long QT syndrome, congestive heart failure, bradyarrhythmias, or clinically significant uncorrected electrolyte imbalance, particularly hypokalemia <3 mmol/L unless corrected;
- •9. Presence of a serious illness, active infection, medical condition, organ system dysfunction, or other factors which, in the Investigator's opinion, could compromise the subject's safety, negatively interact with AT13387, or compromise the integrity of the study outcomes;
- •10. Hypersensitivity to AT13387 or other components of the drug product;
- •11. For Part C, subjects who discontinued treatment with crizotinib due to a crizotinib-related toxicity;
- •12. Treatment with any investigational drug within 3 weeks prior to the first dose of study drug or at least until any residual clinically significant toxicity from the investigational agent has resolved to ? Grade 1 and at least 5 pharmacokinetic half-lives (if known) have elapsed;
- •13. Subjects who are a poor medical risk because of other systemic diseases or active uncontrolled infections; or
- •14. Known history of human immunodeficiency virus or seropositive test for hepatitis C virus or hepatitis B virus.
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to investigate the safety and effect of a drug called AT13387 on its own or given with another drug Abiraterone Acetate on certain types of Prostate Cancer that does not respond to treatment with Abiraterone alone.Castration-Resistant Prostate Cancer (CRPC)MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001574-28-GBAstex Pharmaceuticals Inc49
进行中（未招募）
不适用
A clinical trial to investigate the safety and effect of a drug called AT13387 on its own or given with another drug Abiraterone Acetate on certain types of Prostate Cancer that does not respond to treatment with Abiraterone alone.Castration-Resistant Prostate Cancer (CRPC)MedDRA version: 14.1Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001574-28-ESAstex Pharmaceuticals Inc164
已完成
1 期
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With CrizotinibNon-small Cell Lung Cancer(NSCLC)NCT01712217Astex Pharmaceuticals, Inc.220
已完成
不适用
Imaging the effect of HSP90 inhibitor AUY922 on HER2 expression by means of 89Zr-trastuzumab PET. A side study to the phase I-II study with AUY922 in either HER2 or ER positive locally advanced or metastatic breast cancer: protocol CAUY922A2101.mammary carcinoma1001471010006232breast cancerNL-OMON33851niversitair Medisch Centrum Groningen11
已完成
1 期
AT13387 in Adults With Refractory Solid TumorsSolid TumorsBreast CancerNCT01246102National Cancer Institute (NCI)31